Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by UMB Bank n.a.

UMB Bank n.a. lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 52.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 313,433 shares of the biopharmaceutical company’s stock after acquiring an additional 107,976 shares during the quarter. UMB Bank n.a.’s holdings in Bristol-Myers Squibb were worth $19,116,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in BMY. Sivia Capital Partners LLC lifted its holdings in Bristol-Myers Squibb by 9.3% during the 1st quarter. Sivia Capital Partners LLC now owns 4,691 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 399 shares in the last quarter. First City Capital Management Inc. raised its stake in shares of Bristol-Myers Squibb by 1.2% in the first quarter. First City Capital Management Inc. now owns 21,427 shares of the biopharmaceutical company’s stock valued at $1,307,000 after acquiring an additional 263 shares in the last quarter. Gateway Investment Advisers LLC boosted its holdings in Bristol-Myers Squibb by 0.4% in the first quarter. Gateway Investment Advisers LLC now owns 111,991 shares of the biopharmaceutical company’s stock valued at $6,830,000 after purchasing an additional 436 shares during the period. Udine Wealth Management Inc. grew its stake in Bristol-Myers Squibb by 2.7% during the 1st quarter. Udine Wealth Management Inc. now owns 37,328 shares of the biopharmaceutical company’s stock worth $2,277,000 after purchasing an additional 972 shares in the last quarter. Finally, Pines Wealth Management LLC increased its holdings in Bristol-Myers Squibb by 8.2% during the 1st quarter. Pines Wealth Management LLC now owns 4,559 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 345 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective for the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Wall Street Zen lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday. Jefferies Financial Group cut their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $58.00.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $48.42 on Friday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The firm has a 50-day simple moving average of $49.34 and a 200-day simple moving average of $55.04. The company has a market capitalization of $98.54 billion, a price-to-earnings ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the business posted ($4.40) EPS. The company’s revenue was down 5.6% on a year-over-year basis. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.